Type of subject: outpatient. 
Informed consent: Subjects must give their signed and dated written informed consent to participate. 
Gender: Male or female. Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception. 
Age: >=40 and <=80 years of age at Screening (Visit 1). 
Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at screening (Visit 1). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. 
Airflow Obstruction: 
Subjects with a measured post-albuterol/salbutamol forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio of <=0.70 at Screening (Visit 1). 
Subjects with a measured post-albuterol/salbutamol FEV1 >=50 and <=70% of predicted normal values calculated using NHANES III reference equations [Hankinson, 1999; Hankinson, 2010] at Screening (Visit 1). 
Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated. 
Symptoms of COPD: Subjects must score 2 or higher on the modified Medical Research Council Dyspnea scale (Visit 1) 
Cardiovascular disease: 
For patients >= 40 years of age: any one of the following: 
Established (i.e. by clinical signs or imaging studies) coronary artery disease (CAD) Established (i.e. by clinical signs or imaging studies) peripheral vascular disease (PVD) Previous stroke Previous MI Diabetes mellitus with target organ disease OR 
For patients >=60 years of age: any 2 of the following: 
Being treated for hypercholesterolemia Being treated for hypertension Being treated for diabetes mellitus Being treated for peripheral vascular disease 

NCT01313676_inc_T1
Visit
outpatient
NCT01313676_inc_T3
Person
Male
NCT01313676_inc_T4
Person
female
NCT01313676_inc_T6
Person
Age
NCT01313676_inc_T7
Value
>=40 and <=80 years
NCT01313676_inc_T8
Person
age
NCT01313676_inc_T9
Temporal
at Screening
NCT01313676_inc_T10
Reference_point
Screening
NCT01313676_inc_T11
Multiplier
>=10 pack-years
NCT01313676_inc_T12
Observation
cigarette smoking
NCT01313676_inc_T13
Temporal
at screening
NCT01313676_inc_T14
Observation
history
NCT01313676_inc_T15
Temporal
prior
NCT01313676_inc_T16
Temporal
current
NCT01313676_inc_T17
Scope
current or prior
NCT01313676_inc_T18
Condition
Previous smokers
NCT01313676_inc_T19
Observation
stopped smoking
NCT01313676_inc_T20
Temporal
for at least 6 months prior to Visit 1
NCT01313676_inc_T21
Reference_point
Visit 1
NCT01313676_inc_T22
Scope
stopped smoking for at least 6 months prior to Visit 1
NCT01313676_inc_T24
Drug
albuterol
NCT01313676_inc_T25
Drug
salbutamol
NCT01313676_inc_T26
Temporal
post-albuterol/salbutamol
NCT01313676_inc_T27
Measurement
forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio
NCT01313676_inc_T28
Value
<=0.70
NCT01313676_inc_T29
Temporal
at Screening
NCT01313676_inc_T30
Qualifier
post-albuterol/salbutamol
NCT01313676_inc_T31
Reference_point
albuterol/salbutamol
NCT01313676_inc_T32
Qualifier
post-albuterol/salbutamol
NCT01313676_inc_T33
Temporal
post-albuterol/salbutamol
NCT01313676_inc_T34
Drug
albuterol
NCT01313676_inc_T35
Drug
salbutamol
NCT01313676_inc_T36
Reference_point
albuterol/salbutamol
NCT01313676_inc_T37
Measurement
FEV1
NCT01313676_inc_T38
Value
>=50 and <=70% of predicted normal values
NCT01313676_inc_T39
Qualifier
using NHANES III reference equations
NCT01313676_inc_T40
Temporal
at Screening
NCT01313676_inc_T41
Reference_point
Screening
NCT01313676_inc_T42
Qualifier
Post-bronchodilator
NCT01313676_inc_T43
Temporal
Post-bronchodilator
NCT01313676_inc_T44
Drug
bronchodilator
NCT01313676_inc_T45
Reference_point
bronchodilator
NCT01313676_inc_T46
Procedure
spirometry
NCT01313676_inc_T47
Temporal
approximately 15 minutes after
NCT01313676_inc_T48
Multiplier
4
NCT01313676_inc_T49
Procedure
inhalations
NCT01313676_inc_T50
Qualifier
self-administered
NCT01313676_inc_T51
Multiplier
400mcg
NCT01313676_inc_T52
Drug
albuterol
NCT01313676_inc_T53
Drug
salbutamol
NCT01313676_inc_T54
Scope
albuterol/salbutamol
NCT01313676_inc_T55
Procedure
metered dose inhaler (MDI )
NCT01313676_inc_T56
Qualifier
with a valved-holding chamber
NCT01313676_inc_T57
Condition
Symptoms of COPD
NCT01313676_inc_T58
Value
score 2 or higher
NCT01313676_inc_T59
Measurement
modified Medical Research Council Dyspnea scale
NCT01313676_inc_T61
Value
>= 40 years
NCT01313676_inc_T62
Person
age
NCT01313676_inc_T63
Condition
coronary artery disease (CAD)
NCT01313676_inc_T64
Condition
peripheral vascular disease (PVD)
NCT01313676_inc_T65
Condition
stroke
NCT01313676_inc_T66
Temporal
Previous
NCT01313676_inc_T67
Observation
Established
NCT01313676_inc_T68
Observation
clinical signs
NCT01313676_inc_T69
Procedure
imaging studies
NCT01313676_inc_T70
Condition
MI
NCT01313676_inc_T71
Condition
Diabetes mellitus
NCT01313676_inc_T72
Condition
target organ disease
NCT01313676_inc_T74
Temporal
Previous
NCT01313676_inc_T75
Scope
clinical signs or imaging studies
NCT01313676_inc_T76
Observation
Established
NCT01313676_inc_T77
Observation
clinical signs
NCT01313676_inc_T78
Procedure
imaging studies
NCT01313676_inc_T79
Scope
clinical signs or imaging studies
NCT01313676_inc_T80
Value
>=60 years
NCT01313676_inc_T81
Person
age
NCT01313676_inc_T82
Condition
hypercholesterolemia
NCT01313676_inc_T83
Procedure
treated for hypercholesterolemia
NCT01313676_inc_T84
Procedure
treated for hypertension
NCT01313676_inc_T85
Condition
hypertension
NCT01313676_inc_T86
Condition
diabetes mellitus
NCT01313676_inc_T87
Procedure
treated for diabetes mellitus
NCT01313676_inc_T88
Procedure
treated for peripheral vascular disease
NCT01313676_inc_T89
Condition
peripheral vascular disease